Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Almac Group.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Almac Group
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
Almac House, 20 Seagoe Industrial Estate, Craigavon BT63 5QD
Telephone
Telephone
+44 283 833 2200

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The agreement aims for the potential launch and commercialization of Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets), a centrally acting, non-opioid medication, in the US.


Lead Product(s): Cyclobenzaprine

Therapeutic Area: Musculoskeletal Product Name: Tonmya

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 20, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This funding supports efforts to combat the COVID-19 pandemic through the rapid process development and manufacturing of remdesivir.


Lead Product(s): Remdesivir

Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: COVID-19 Therapeutics Accelerator

Deal Size: $0.5 million Upfront Cash: Undisclosed

Deal Type: Funding November 17, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Presentations highlight significant new data for key oncology drug development programmes - USP7 small molecule inhibitors and ROR1 Protein: Drug Conjugates.


Lead Product(s): ADP-c165

Therapeutic Area: Oncology Product Name: ADP-c165

Highest Development Status: DiscoveryProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The agreement aims at advancing the development and commercialisation of Almac's portfolio projects – ALM301. The molecule is currently in late-stage pre-clinical development, and the partner will complete this before progressing into the clinical development phase.


Lead Product(s): ALM301

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 14, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Research collaboration will focus on developing new small molecule inhibitors against specific targets of Deubiquitinase to treat a variety of neurodegenerative and other diseases.


Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 29, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY